Initiate a US Phase 1 clinical trial for OTX-TKI
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Plan to initiate US Phase 1 Trial mid-2021”
What we found
Evidence strength A What the grades mean
The company initiated the U.S. Phase 1 clinical trial for OTX-TKI in July 2021, which is after the mid-2021 deadline.
-
A Ocular Therapeutix, Inc. 10-K filed 2022-02-28
“United States Phase 1 trial initiated in July 2021.” ✓ confirmed on the page
Market reaction: the shares moved -1.8% against the S&P 500 over the three sessions around the disclosure (25 Feb 2022 to 2 Mar 2022). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- US Phase 1 clinical trial for OTX-TKI
- Where
- US
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Ocular Therapeutix, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OCUL-021433 · Corrections policy